CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
Zolmitriptan is a 5-HT1B/1D-angiotensin receptor (5-HT1B/1D-AR) partial agonist with Ki's of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, and 5-HT1F receptors, respectively.Zolmitriptan can be used in studies related to migraine.
Zolmitriptan is a 5-HT1B/1D-angiotensin receptor (5-HT1B/1D-AR) partial agonist with Ki's of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, and 5-HT1F receptors, respectively.Zolmitriptan can be used in studies related to migraine.
Zomepirac Sodium is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor.
Zomepirac Sodium is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor.
Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity.
Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity.
Zonisamide is an fDA-approved antiepileptic compound that blocks voltage-dependent sodium (+) and T-type calcium channels.